SCHEDULE: Biogen to Tender Sage Therapeutics Shares After Failed Acquisition Bid

Biogen Inc. plans to tender its 10% stake in Sage Therapeutics, Inc. following the rejection of its acquisition proposal and Sage's subsequent merger agreement with Supernus Pharmaceuticals, Inc.

Summary

• Biogen Inc. and its subsidiary, Biogen MA Inc., collectively hold 6,241,473 shares of Sage Therapeutics, Inc. common stock, representing 10% of the outstanding class.
• From March through May 2025, Biogen engaged in discussions and diligence with Sage Therapeutics regarding a potential acquisition.
• On May 5, 2025, Biogen submitted a non-binding proposal to acquire all outstanding Sage shares not owned by Biogen for an upfront payment of $9.00 per share in cash, plus two contingent value rights (CVRs) totaling $4.00 per share based on ZURZUVAE U.S. net sales milestones ($2.00 at $450 million and $2.00 at $700 million).
• Sage Therapeutics terminated all discussions with Biogen regarding a potential transaction on May 15, 2025.
• On June 16, 2025, Sage Therapeutics announced it had entered into a merger agreement, dated June 13, 2025, with Supernus Pharmaceuticals, Inc. and its subsidiary, Saphire, Inc.
• Under the Supernus agreement, a tender offer was commenced to acquire all of Sage's shares for $8.50 per share in cash plus one CVR per share representing the right to receive up to $3.50 per share upon the satisfaction of certain milestones.
• The Supernus tender offer commenced on July 2, 2025, and is currently scheduled to expire at 11:59 P.M. Eastern Time on July 30, 2025.
• Biogen Inc. intends to tender all or a portion of its Sage Therapeutics common stock to Supernus's tender offer or otherwise dispose of its shares.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative for Biogen as their acquisition bid was rejected in favor of a lower offer from a competitor, indicating a missed strategic opportunity. For Sage, it's positive as they secured an acquisition, but the accepted offer was lower than Biogen's proposal.

Positives

• Sage Therapeutics secured a merger agreement with Supernus Pharmaceuticals, Inc., providing a clear acquisition path for its shareholders.
• The Supernus offer includes an upfront cash component of $8.50 per share, providing immediate liquidity to Sage shareholders.
• The Supernus offer includes contingent value rights (CVRs) up to $3.50 per share, offering potential additional value based on future milestones.

Negatives

• Biogen Inc.'s non-binding proposal to acquire Sage Therapeutics for $9.00 cash plus $4.00 in CVRs was rejected by Sage.
• Sage Therapeutics terminated all discussions with Biogen regarding a potential transaction, indicating a missed strategic acquisition opportunity for Biogen.
• The accepted Supernus offer of $8.50 cash plus up to $3.50 in CVRs represents a lower total potential value ($12.00 per share) compared to Biogen's rejected proposal ($13.00 per share).

Risks

• The actual value realized from the contingent value rights (CVRs) in the Supernus offer is uncertain and dependent on the achievement of specific milestones, which may not occur.
• Biogen's stated intent to tender or dispose of its 10% stake in Sage Therapeutics could potentially create selling pressure on Sage's stock if not fully absorbed by the tender offer.

Future Outlook

Biogen Inc. intends to tender all or a portion of its 6,241,473 shares of Sage Therapeutics, Inc. common stock into the Supernus Pharmaceuticals, Inc. tender offer, which is scheduled to expire on July 30, 2025, or otherwise dispose of its shares. Biogen does not intend to disclose further developments unless required by applicable law.

Industry Context

This filing highlights ongoing consolidation and M&A activity within the biotechnology and pharmaceutical sectors, particularly concerning companies with promising drug candidates like ZURZUVAE. The competitive bidding process for Sage Therapeutics, involving Biogen and Supernus, underscores the strategic value placed on late-stage assets and market access in the industry.

Stakeholder Impact

• Shareholders of Sage Therapeutics will receive cash and contingent value rights if they tender their shares into the Supernus offer, providing liquidity and potential future upside.
• Biogen Inc., as a significant shareholder of Sage, will dispose of its investment, impacting its portfolio and strategic focus.
• Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, expanding its product portfolio and market presence, particularly with ZURZUVAE.

Next Steps

• Biogen Inc. intends to tender all or a portion of its common stock in Sage Therapeutics, Inc. to Supernus Pharmaceuticals, Inc.'s tender offer.
• Biogen Inc. may also dispose of all or a portion of its common stock in Sage Therapeutics, Inc. outside of the tender offer.
• Supernus Pharmaceuticals, Inc.'s tender offer for Sage Therapeutics shares is scheduled to expire on July 30, 2025.

Key Dates

Recommendation

Keywords

Sage Therapeutics, Biogen Inc., Supernus Pharmaceuticals, Tender Offer, Merger Agreement, Acquisition Proposal, Contingent Value Rights, ZURZUVAE, SEC Filing, Biotechnology, Pharmaceuticals